Clinical Trials Logo

Pleural Biphasic Mesothelioma clinical trials

View clinical trials related to Pleural Biphasic Mesothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05647265 Recruiting - Clinical trials for Pleural Biphasic Mesothelioma

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.

NCT ID: NCT04158141 Terminated - Clinical trials for Pleural Epithelioid Mesothelioma

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Start date: January 29, 2020
Phase: Phase 3
Study type: Interventional

This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery and chemotherapy may work better than surgery and chemotherapy alone for the treatment of malignant pleural mesothelioma.

NCT ID: NCT02399371 Active, not recruiting - Clinical trials for Pleural Malignant Mesothelioma

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Start date: March 31, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.